Stool test for colorectal cancer screening - it's time to move!

Clinical Laboratory

Volumn 54, Issue 11-12, 2008, Pages 473-484

  Loitsch, S M ^a   Shastri, Y ^a   Stein, Jürgen ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Calprotectin; Colon cancer; DNA; Fecal occult blodd test; M2 PK

Indexed keywords

APC PROTEIN; BIOLOGICAL MARKER; CALGRANULIN; CELL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA MARKER; K RAS PROTEIN; LACTOFERRIN; LEUKOCYTE MARKER; LONG DNA; LYSOZYME; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MOLECULAR MARKER; PROTEIN BAT26; PROTEIN HIC1; PROTEIN MLH1; PROTEIN P16; PROTEIN P53; PYRUVATE KINASE; PYRUVATE KINASE ISOENZYME M 2; SECRETED FRIZZLED RELATED PROTEIN 2; UNCLASSIFIED DRUG; VIMENTIN;

ARTICLE; CANCER MORTALITY; CANCER SCREENING; CLINICAL TRIAL; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; CPG ISLAND; DIAGNOSTIC ACCURACY; DIET RESTRICTION; DNA DETERMINATION; DNA METHYLATION; EARLY DIAGNOSIS; FALSE POSITIVE RESULT; FECES ANALYSIS; GENETIC MARKER; GUAIAC BASED FECAL OCCULT BLOOD TEST; HUMAN; IMMUNOLOGY BASED FECAL OCCULT BLOOD TEST; INTERMETHOD COMPARISON; MICROSATELLITE INSTABILITY; NON INVASIVE PROCEDURE; NONHUMAN; OCCULT BLOOD; SENSITIVITY AND SPECIFICITY;

COLORECTAL NEOPLASMS; DNA METHYLATION; FECES; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MASS SCREENING; OCCULT BLOOD; PYRUVATE KINASE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 60549092480     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Ahlquist DA, McGill DB, Fleming JL et al. Patterns of occult bleeding in asymptomatic colorectal cancer. Cancer 1989; 63: 1826-30.
2. Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Pierceall WE, Thibodeau SN, Shuber AP. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000; 119: 1219-27.
3. Arnold CN, Blum HE. Colon cancer: molecular markers Dtsch Med Wochenschr. 2005; 130: 880-2.
4. Boland CR, Sato J, Appelman HD, Bresalier RS, Feinberg AP. Microallelotyping defines the sequence and tempo of allelic losses at tumour suppressor gene loci during colorectal cancer progression. Nat Med 1995; 1: 902-9.
5. Bos JL Ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-9.
6. Boynton KA, Summerhayes IC, Ahlquist DA, Shuber AP. DNA integrity as a potential marker for stool-based detection of colorectal cancer. Clin Chem 2003; 49: 1058-65.
7. Bampton PA, Sandford JJ, Cole SR, Smith A, Morcom J, Cadd B, et al. Interval faecal occult blood testing in a colonoscopy based screening programme detects additional pathology. Gut. 2005; 54: 803-806.
8. Calistri D, Rengucci C, Bocchini R, Saragoni L, Zoli W, Amadori D. Fecal multiple molecular tests to detect colorectal cancer in stool. Clin Gastroenterol Hepatol 2003; 1: 377-83.
9. Cole SR, Young GP. Effect of dietary restriction on participation in faecal occult blood test screening for colorectal cancer. Med J Aust 2001; 175: 195-8.
10. Davies RJ, Miller R, Coleman N. Colorectal cancer screening: prospects for molecular stool analysis. Nat Rev Cancer. 2005; 5: 199-209.
11. Dubrow R, Kim CS, Eldred AK. Fecal lysozyme: an unreliable marker for colorectal cancer. Am J Gastroenterol 1992; 87: 617-21.
12. Eguchi S, Kohara N, Komuta K, Kanematsu T Mutations of the p53 gene in the stool of patients with respectable colorectal cancer. Cancer 1996; 77: 1707-10.
13. Fearon ER, Cho KR, Nigro JM et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 1990; 247: 49-56.
14. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, version 1.0. IARC Cancer Base 5. Lyon: IARC, 2001, http://www-dep.iarc.fr/globocan/globocan.html.
15. Frattini M, Balestra D, Pilotti S, Bertario L, Pierotti MA. Tumor location and detection of k-ras mutations in stool from colorectal cancer patients. J Natl Cancer Inst 2003; 95: 72-3.
16. Greenberg PD, Bertario L, Gnauck R, Kronborg O, Hardcastle JD, Epstein MS, Sadowski D, Sudduth R, Zuckerman GR, Rockey DC. A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy. Am J Gastroenterol 2000; 95: 1331-8.
17. Hardcastle J, Chamberlain J, Robinson M, Moss S, Amar S, Balfour T, et al. Randomised controlled trial of faecal-blood screening for colorectal cancer. Lancet 1996; 348:1472-7.
18. Hardt PD, Toepler M, Ngoumou B, Rupp J, Kloer HU. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Anticancer Res. 2003; 23: 851-3.
19. Hardt PD, Mazurek S, Toepler M, Schlierbach P, Bretzel RG, Eigenbrodt E, Kloer HU. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer 2004; 91: 980-4.
20. Haug U, Brenner H. New stool tests for colorectal cancer screening: a systematic review focusing on performance characteristics and practicalness. Int J Cancer. 2005; 117: 169-76.
21. Haug U, Rothenbacher D, Wente MN, Seiler CM, Stegmaier C, Brenner H. Tumour M2-PK as a stool marker for colorectal cancer: comparative analysis in a large sample of unselected older adults vs colorectal cancer patients. Br J Cancer. 2007; 96(9): 1329-34.
22. 20a. Haug U, Hundt S, Brenner H.Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study.Br J Cancer. 2008 Jun 10.
23. Hoepffner N, Shastri YM, Hanisch E, Rosch W, Mossner J, Caspary WF, Stein J. Comparative evaluation of a new bedside faecal occult blood test in a prospective multicentre study. Aliment Pharmacol Ther. 2006; 23: 145-54.
24. Hoff G, Grotmol T, Thiis-Evensen E, Bretthauer M, Gondal G, Vatn MH. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT). Gut 2004; 53: 1329-33.
25. Johne B, Kronborg O, Ton HI, Kristinsson J, Fuglerud P. A new fecal calprotectin test for colorectal neoplasia. Clinical results and comparison with previous method. Scand J Gastroenterol 2001; 36: 291-296.
26. Kewenter J, Bjork S, Haglind E, Smith L, Svanvik J, Ahren C. Screening and rescreening for colorectal cancer. A controlled trial of fecal occult blood testing in 27,000 subjects. Cancer 1988; 62: 645-51.
27. Kinzler KW, Vogelstein B Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-70.
28. Koshiji M, Yonekura Y, Saito T, Yoshioka K. Microsatellite analysis of fecal DNA for colorectal cancer detection. J Surg Oncol 2002; 80: 34-40.
29. Kristinsson J, Nygaard K, Aadland E, Barstad S, Sauar J, Hofstad B, Stray N, Stallemo A, Haug B, Ugstad M, Ton H, Fuglerud P. Screening of first degree relatives of patients operated for colorectal cancer: evaluation of fecal calprotectin vs. hemoccult II. Digestion 2001; 64: 104-10.
30. Kronborg O, Fenger C, Olsen J, Jorgensen O, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348: 1467-71.
31. Kronborg O, Ugstad M, Fuglerud P, Johne B, Hardcastle J, Scholefield JH, Vellacott K, Moshakis V, Reynolds JR. Faecal calprotectin levels in a high risk population for colorectal neoplasia. Gut 2000; 46: 795-800.
32. Launoy GD, Bertrand HJ, Berchi C, Talbourdet VY, Guizard AV, Bouvier VM, et al. Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population. Int J Cancer. 2005; 115: 493-6.
33. Leung WK, To KF, Man EP, Chan MW, Hui AJ, Ng SS, Lau JY, Sung JJ. Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps. Am J Gastroenterol 2007; 102: 1070-6.
34. Levi Z, Hazazi R, Rozen P, Vilkin A, Waked A, Niv Y. A quantitative immunochemical faecal occult blood test is more efficient for detecting significant colorectal neoplasia than a sensitive guaiac test. Aliment Pharmacol Ther. 2006; 23: 1359-64.
35. Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E, Birkenfeld S, Leshno M, Niv Y. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med. 2007; 146: 244-55.
36. Li S, Wang H, Hu J, Li N, Liu Y, Wu Z, Zheng Y, Wang H, Wu K, Ye H, Rao J. New immunochemical fecal occult blood test with two-consecutive stool sample testing is a cost-effective approach for colon cancer screening: Results of a prospective multicenter study in Chinese patients. Int J Cancer. 2006; 118: 3078-83.
37. Lieberman DA, Weiss DG; Veterans Affairs Cooperative Study Group.One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med. 2001 Aug; 345: 555-60.
38. Limburg PJ, Devens ME, Harrington JJ, Diehl NN, Mahoney DW, Ahlquist DA. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia. Am J Gastroenterol 2003; 98: 2299-305.
39. Loktionov A, O'Neill IK, Silvester KR, Cummings JH, Middleton SJ, Miller R. Quantitation of DNA from exfoliated colonocytes isolated from human stool surface as a novel noninvasive screening test for colorectal cancer. Clin Cancer Res 1998; 4: 337-42.
40. Macrae FA, St. John DJ Relationship between patterns of bleeding and hemoccult sensitivity in patients with colorectal cancers or adenomas. Gastroenterology 1982; 82: 891-98.
41. Mandel J, Bond J, Church T, Snover D, Bradley G, Schuman L, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993; 328:1365-71.
42. Mandel J, Church T, Bond J, Ederer F, Geisser M, Mongin S, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000; 343:1603-1607.
43. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology. 2005; 129: 422-8.
44. Muller HM, Oberwalder M, Fiegl H, Morandell M, Goebel G, Zitt M, Muhlthaler M, Ofner D, Margreiter R, Widschwendter M. Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet 2004; 363: 1283-5.
45. Nakama H, Zhang B, Zhang X. Evaluation of the optimum cut-off point in immunochemical occult blood testing in screening for colorectal cancer. Eur J Cancer. 2001; 37: 398-401.
46. Naumann M, Schaum B, Oremek GM, Hanisch E, Rosch W, Mossner J, Caspary WF, Stein J. Faecal pyruvate kinase type M2-a valid screening parameter for colorectal cancer? Preliminary results from a multicenter comparative study. Dtsch Med Wochenschr. 2004; 129: 1806-7.
47. Puig P, Urgell E, Capella G, Sancho FJ, Pujol J, Boadas J, Farre A, Lluis F, Gonzalez-Sastre F, Mora J. A highly sensitive method for K-ras mutation detection is useful in diagnosis of gastrointestinal cancer. Int J Cancer 2000; 85: 73-7.
48. Ransohoff DF, Lang CA Screening for colorectal cancer with the fecal occult blood test: a background paper. Ann Intern Med 1997; 126: 811-22.
49. Ratto C, Flamini G, Sofo L et al. Detection of oncogene mutation from neoplastic colonic cells exfoliated in feces. Dis Colon Rectum 1996; 39: 1238-44.
50. Roseth AG, Kristinsson J, Fagerhol MK, Schjonsby H, Aadland E, Nygaard K, Roald B. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol 1993; 28: 1073-76.
51. Rozen P, Knaani J, Samuel Z. Eliminating the need for dietary restrictions when using a sensitive guaiac fecal occult blood test. Dig Dis Sci. 1999; 44: 756-60.
52. Saito H Screening for colorectal cancer: current status in Japan. Dis Colon Rectum. 2000; 43(10 Suppl): S78-84.
53. Schneider AR, Caspary WF. Diagnosis of colorectal carcinoma. An update. Radiologe. 2003;43:105-112.
54. Shastri YM, Naumann M, Oremek GM, Hanisch E, Rosch W, Mossner J, Caspary WF, Stein J Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia. Int J Cancer 2006; 119: 2651-6.
55. Shastri Y, Stein J. Fecal tumor M2 pyruvate kinase is not a specific biomarker for colorectal cancer screening. World J Gastroenterol 2007;13:2769-70.
56. Shastri YM, Loitsch S, Hoepffner N, Povse N, Hanisch E, Rösch W, Mössner J, Stein JM. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study. Am J Gastroenterol. 2008; 103(6):1496-504.
57. Shastri YM, Stein J. Quantitative immunochemical fecal occult blood test for diagnosing colorectal neoplasia. Ann Intern Med. 2007; 147: 522-3.
58. Shastri YM, Stein J New faecal tests for colorectal cancer screening: is tumour pyruvate kinase M2 one of the options? Br J Cancer. 2007; 97(11):1595-6.
59. Sieg A, Thorns C, Luthgens K, John MR, Schmidt-Gayk H. Detection of colorectal neoplasms by the highly sensitive hemoglobin-haptoglobin complex in feces. Int J Colorectal Dis. 1999; 14: 267-71.
60. Smith A, Young GP, Cole SR, Bampton P. Comparison of a Brush-Sampling Fecal Immunochemical Test for Hemoglobin With a Sensitive Guaiac-Based Fecal Occult Blood Test in Detection of Colorectal Neoplasia. Cancer 2006; 107: 2152-9.
61. Song K, Fendrick AM, Ladabaum U. Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology 2004; 126: 1270-9.
62. Summerton C, Longlands M, Wiener K, Shreeve D. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 2002; 14: 841-845.
63. Tagore KS, Lawson MJ, Yucaitis JA, Gage R, Orr T, Shuber AP, Ross ME. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin Colorectal Cancer 2003; 3: 47-53.
64. Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagerhol M, Bjarnason I. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 2001; 49: 402-8.
65. Tonus C, Neupert G, Sellinger M. Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK. World J Gastroenterol 2006;12:7007-11.
66. Towler, B. P., Irwig, L., Glasziou, P., Weller, D. & Kewenter, J. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst. Rev. 2, CD001216 (1998).
67. Traverso G, Shuber A, Levin B et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors.N Engl J Med 2002; 346: 311-320.
68. Traverso G, Shuber A, Olsson L, Levin B, Johnson C, Hamilton SR, Boynton K, Kinzler KW, Vogelstein B. Detection of proximal colorectal cancers through analysis of faecal DNA. Lancet 2002; 359: 403-4.
69. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006; 55: 426-31.
70. Vilkin A, Rozen P, Levi Z, Waked A, Maoz E, Birkenfeld S, et al. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol. 2005; 100: 2519-25.
71. Villa E, Dugani A, Rebecchi AM et al. Identification of subjects at risk for colorectal carcinoma through a test based on K-ras determination in the stool. Gastroenterology 1996; 110: 1346-53.
72. Vogel T, Driemel C, Hauser A, Hansmann A, Lange S, Jonas M, Moslein G. Comparison of different stool tests for the detection of cancer of the colon. Dtsch Med Wochenschr. 2005; 130: 872-7.
73. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-32.
74. Walkowiak J, Banasiewicz T, Krokowicz P, Hansdorfer-Korzon R, Drews M, Herzig KH Fecal pyruvate kinase (M2-PK): a new predictor for inflammation and severity of pouchitis. Scand J Gastroenterol. 2005; 40: 1493-4.
75. Wan J, Zhang ZQ, You WD, Sun HK, Zhang JP, Wang YH, Fu YH. Detection of K-ras gene mutation in fecal samples from elderly large intestinal cancer patients and its diagnostic significance. World J Gastroenterol 2004; 10: 743-6.
76. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, Ganiats T, Levin T, Woolf S, Johnson D, Kirk L, Litin S, Simmang C; Gastrointestinal Consortium Panel. Colorectal cancer screening and surveillance: Clinical guidelines and rationale-Update based on new evidence. Gastroenterology. 2003; 124: 544-60.
77. Wong BC, Wong WM, Cheung KL, Tung TS, Rozen P, Young GP, Chu KW, Hu J, Law WL, Tung HM, Hu WH, Chan CK, et al. A sensitive guaiac fecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population. Aliment Pharmacol Ther 2003; 18: 941-6.
78. Wong WM, Lam SK, Cheung KL, Tong TS, Rozen P, Young GP, Chu KW, Ho J, Law WL, Tung HM, Choi HK, Lee YM, Lai KC, Hu WH, Chan CK, Yuen MF, Wong BC. Evaluation of an automated immunochemical fecal occult blood test for colorectal neoplasia in a Chinese population. Cancer 2003; 97: 2420-4.
79. Nagasaka T, Goel A, Matsubara N, Tanaka N. Detection of fecal DNA methylation for colorectal neoplasia: does it lead to an optimal screening test? Acta Med Okayama. 2006; 60(5): 249-56.
80. Itzkowitz SH, Jandorf L, Brand R, Rabeneck L, Schroy PC 3rd, Sontag S, Johnson D, Skoletsky J, Durkee K, Markowitz S, Shuber A. Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol. 2007; 5(1): 111-7.
81. Chen WD, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L, Platzer P, Lu S, Dawson D, Willis J, Pretlow TP, Lutterbaugh J, Kasturi L, Willson JK, Rao JS, Shuber A, Markowitz SD. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst. 2005, 97: 1124-32.
82. Lenhard K, Bommer GT, Asutay S, Schauer R, Brabletz T, Göke B, Lamerz R, Kolligs FT. Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin Gastroenterol Hepatol. 2005, 3(2): 142-9.
83. Petko Z, Ghiassi M, Shuber A, Gorham J, Smalley W, Washington MK, Schultenover S, Gautam S, Markowitz SD, Grady WM. Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin Cancer Res. 2005, 11(3): 1203-9.
84. Kang MY, Lee BB, Ji YI, Jung EH, Chun HK, Song SY, Park SE, Park J, Kim DH. Association of interindividual differences in p14(ARF) promoter methylation with single nucleotide polymorphism in primary colorectal cancer. Cancer. 2008.